

A World of Pain: The Undertreatment of Chronic Pain

References

1. Brookoff D. Chronic pain: 1. A new disease? *Hosp Pract.* 2000;35:45-52, 59.
2. Reyes-Gibby CC. Data from the Health and Retirement Study. Analyses courtesy of C. Reyes-Gibby, MD, Houston, Texas, 2005.
3. Reyes-Gibby CC, Aday L, Cleeland C. Impact of pain on self-rated health in the community-dwelling older adults. *Pain.* 2002;95: 75-82.
4. Bennett GJ. Neuropathic pain: new insights, new interventions. *Hosp Pract.* 1998;33:95-114.
5. American Pain Society. Chronic pain in America: roadblocks to relief. Available at: http://www.ampainsoc.org/whatsnew/summary2_road.htm. Accessed March 9, 2006.
6. Andersson GB. Epidemiological features of chronic low-back pain. *Lancet.* 1999;354:581-585.
7. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. *JAMA.* 2003;290:2443-2454.
8. Skevington SM. Investigating the relationship between pain and discomfort and quality of life, using the WHOQOL. *Pain.* 1998;76: 395-406.
9. Elliott TE, Renier CM, Palcher JA. Chronic pain, depression, and quality of life: correlations and predictive value of the SF-36. *Pain Med.* 2003;4:331-339.
10. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. *Pain.* 2004;111:77-83.
11. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. *Am J Manag Care.* 2004;10: 313-320.
12. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med.* 1994;330: 592-596.
13. Unruh AM. Gender variations in clinical pain experience. *Pain.* 1996;65:123-167.
14. Todd KH, Deaton C, D'Adamo AP, Goe L. Ethnicity and analgesic practice. *Ann Emerg Med.* 2000;35:11-16.
15. Todd KH, Samaroo N, Hoffman JR. Ethnicity as a risk factor for inadequate emergency department analgesia. *JAMA.* 1993;269: 1537-1539.
16. Bernabei R, Gambassi G, Lapane K, et al. SAGE Study Group. Management of pain in elderly patients with cancer. *JAMA.* 1998; 279:1877-1882.
17. Baier RR, Gifford DR, Patry G, et al. Ameliorating pain in nursing homes: a collaborative quality-improvement project. *J Am Geriatr Soc.* 2004;52:1988-1995.

Understanding Pain Mechanisms

References

1. Brookoff D. Chronic pain: 1. A new disease? *Hosp Pract.* 2000;35:45-52, 59.
2. Portenoy RK. Opioid analgesics. In: Portenoy RK, Kanner RM, eds. *Pain Management: Theory and Practice*. Philadelphia, Pa: FA Davis Co; 1996:248-276.
3. Turk DC, Melzack R. The measurement of pain and the assessment of people experiencing pain. In: Turk DC, Melzack R, eds. *Handbook of Pain Assessment*. 2nd ed. New York, NY: The Guilford Press; 2001:3-11.
4. Nicholson BD. Diagnosis and management of neuropathic pain: a balanced approach to treatment. *J Am Acad Nurse Pract.* 2003;15(12 suppl):3-9.
5. International Association for the Study of Pain. IASP pain terminology. Available at: <http://www.iasp-pain.org/terms-p.html#Neuropathic%20pain>. Accessed March 9, 2006.
6. National Pharmaceutical Council, Inc, Joint Commission on Accreditation of Healthcare Organizations. *Pain: Current Understanding of Assessment, Management, and Treatments*. December 2001.
7. Gottschalk A, Smith DS. New concepts in acute pain therapy: preemptive analgesia. *Am Fam Physician.* 2001;63:1979-1984.
8. Bolay H, Moskowitz MA. Mechanisms of pain modulation in chronic syndromes. *Neurology.* 2002;59(suppl 2):S2-S7.
9. Marcus DA. Treatment of nonmalignant chronic pain. *Am Fam Physician.* 2000;61:1331-1338, 1345-1346.
10. Scholz J, Woolf CJ. Can we conquer pain? *Nat Neurosci.* 2002;5(suppl):1062-1067.
11. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet.* 1999;353:1959-1964.
12. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol.* 2003;60:1524-1534.

Pain Assessment

References

1. American Pain Society. *Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain*. 5th ed. Glenview, Ill: American Pain Society; 2003.
2. McCaffery M, Pasero C. Assessment: underlying complexities, misconceptions, and practical tools. In: McCaffery M, Pasero C, eds. *Pain: Clinical Manual*. 5th ed. St. Louis, Mo: Mosby, Inc; 1999:36-102.
3. National Pharmaceutical Council, Inc, Joint Commission on Accreditation of Healthcare Organizations. *Pain: Current Understanding of Assessment, Management, and Treatments*. December 2001.
4. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. *Clin J Pain*. 2002;18:297-301.
5. Ramelet A-S, Abu-Saad HH, Rees N, McDonald S. The challenges of pain measurement in critically ill young children: a comprehensive review. *Aust Crit Care*. 2004;17:33-45.
6. Craig KD, Korol CT, Pillai RR. Challenges of judging pain in vulnerable infants. *Clin Perinatol*. 2002;29:445-457.
7. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. *Drugs Aging*. 2003;20:23-57.
8. Brunton S. Approach to assessment and diagnosis of chronic pain. *J Fam Pract*. 2004;53(suppl 10):S3-S10.
9. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore*. 1994;23:129-138.
10. Melzack R, Katz J. Pain measurement in persons in pain. In: Wall PD, Melzack R, eds. *Textbook of Pain*. 4th ed. London, England: Churchill Livingstone; 1999:409-426.
11. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. *Neurology*. 1997;48:332-338.
12. Grossman SA, Sheidler VR, Swedeon K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. *J Pain Symptom Manage*. 1991;6:53-57.
13. Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management: a survey from the Eastern Cooperative Oncology Group. *Ann Intern Med*. 1993;119:121-126.
14. MacMillan K. Multidimensional pain assessment. Nursing Notes. Available at: <http://www.palliative.org/PC/ClinicalInfo/NursesNotes/Multidimensional.html>. Accessed May 2, 2006.
15. American Pain Society. *Guideline for the Management of Cancer Pain in Adults and Children*. APS Clinical Practice Guideline Series, No. 3. Glenview, Ill: American Pain Society; 2005.

Multimodal Approach to Chronic Pain Management

References

1. American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. *J Am Geriatr Soc.* 2002;50:S205-S224.
2. Portenoy RK. Opioid analgesics. In: Portenoy RK, Kanner RM, eds. *Pain Management: Theory and Practice*. Philadelphia, Pa: FA Davis Co; 1996:248-276.
3. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. *Clin J Pain.* 2002;18:297-301.
4. Katz N, Davis MW, Dworkin R. Topical lidocaine patch produces a significant improvement in quality of life indicators in treated PHN patients: results of a multicenter open-label trial. *Pain Med.* 2001;2:242-243. Abstract 212.
5. Belgrade MJ. Following the clues to neuropathic pain: distribution and other leads reveal the cause and the treatment approach. *Postgrad Med.* 1999;106:127-140.
6. Gonzales GR. Central pain: diagnosis and treatment strategies. *Neurology.* 1995;45(suppl 9):S11-S16.
7. Argoff CE. Topical analgesics: a review of recent clinical trials and their application to clinical practice. *Adv Stud Med.* 2003;3: S642-S647.
8. Portenoy RK, Kanner RM. Nonopioid and adjuvant analgesics. In: Portenoy RK, Kanner RM, eds. *Pain Management: Theory and Practice*. Philadelphia, Pa: FA Davis Co; 1996:219-247.
9. Duragesic® [fentanyl transdermal system] [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, LP; 2003. Available at: <http://www.fda.gov/cder/drug/infopage/fentanyl/DuragesicPPI.pdf>. Accessed June 1, 2006.
10. Reisner L. Antidepressants for chronic neuropathic pain. *Curr Pain Headache Rep.* 2003;7:24-33.
11. Beydoun A, Backonja M-M. Mechanistic stratification of antineuritic agents. *J Pain Symptom Manage.* 2003;25(5 suppl): S18-S30.
12. Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. *Anesth Analg.* 1993;77: 1048-1056.
13. Preskorn SH. Polypharmacy: when is it rational? Available at: <http://www.preskorn.com/columns/9507.html>. Accessed April 14, 2006.
14. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol.* 2003;60:1524-1534.
15. American Pain Society. *Guideline for the Management of Cancer Pain in Adults and Children. APS Clinical Practice Guideline Series, No. 3.* Glenview, Ill: American Pain Society; 2005.

Neuropathic Pain

References

1. Bennett GJ. Neuropathic pain: new insights, new interventions. *Hosp Pract.* 1998;33:95-114.
2. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet.* 1999;353:1959-1964.
3. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. *Clin J Pain.* 2002;18:350-354.
4. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. *Eur J Pain.* 1999;3:335-342.
5. Turk DC. Are pain syndromes acute or chronic diseases [editorial]? *Clin J Pain.* 2000;16:279-280.
6. Belgrade MJ. Following the clues to neuropathic pain: distribution and other leads reveal the cause and the treatment approach. *Postgrad Med.* 1999;106:127-140.
7. Kim K-M, Kim H-S, Choi K-H, Ahn W-S. Cephalic spreading levels after volumetric caudal epidural injections in chronic low back pain. *J Korean Med Sci.* 2001;16:193-197.
8. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol.* 2003;60:1524-1534.
9. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. *Pain.* 1999;80:533-538.
10. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. *Clin J Pain.* 2002;18:297-301.
11. Katz N, Davis MW, Dworkin R. Topical lidocaine patch produces a significant improvement in quality of life indicators in treated PHN patients: results of a multicenter open-label trial. *Pain Med.* 2001;2:242-243. Abstract 212.
12. Gonzales GR. Central pain: diagnosis and treatment strategies. *Neurology.* 1995;45(suppl 9):S11-S16.
13. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. *J Am Geriatr Soc.* 2002;50(suppl 6):S205-S224.
14. Ferrell BA, Herr K, Epplin J, et al. The management of persistent pain in older persons. Paper presented at: American Geriatric Society 2002 Annual Scientific Meeting; May 8-12, 2002; Washington, DC.
15. American Medical Association. *Pain Management: Overview of Management Options.* 2003.
16. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. *Diabetes Care.* 1997;20:1702-1705.
17. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L, for the Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA.* 1998;280:1837-1842.
18. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. *Prostaglandins Leukot Essent Fatty Acids.* 2002;66:243-256.
19. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med.* 1992;326:1250-1256.
20. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. *Neurology.* 1998;50:1837-1841.
21. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology.* 1998;50:1842-1846.
22. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. *Pain.* 1999;83:85-90.
23. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Neuralgias and neuropathies. *Headache.* 2005;45:95.
24. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. *Neurology.* 2004;63:2104-2110.
25. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. *Pain.* 2003;106:151-158.
26. Katz NP, Gammaioni AR, Davis MW, Dworkin RH, Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. *Pain Med.* 2002;3:324-332.
27. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. *Drugs.* 2005;64:111-118.
28. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. *Drugs.* 2004;64:2813-2820; discussion 2821.
29. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. *Neurology.* 2003;60:1274-1283.

Neuropathic Pain

References (cont)

30. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. *Pain*. 2004;110:628-638.
31. Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. *Pain*. 2004;109:26-35.
32. Pregabalin: new drug. Very similar to gabapentin. *Prescribe Int*. 2005;14:203-206.
33. La Spina I, Porazzi D, Maggioli F, Bottura P, Suter F. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. *Eur J Neurol*. 2001;8:71-75.
34. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. *Clin J Pain*. 1996;12:56-58.
35. Jagustyn P, Romaniak A. [GABAptentin—new therapeutic possibilities]. *Neurol Neurochir Pol*. 2002;36:971-980.
36. Solaro C, Uccelli MM, Guglieri P, Uccelli A, Mancardi GL. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. *Mult Scler*. 2000;6:192-193.
37. D'Aleo G, Rifici C, Sessa E, Di Bella P, Bramanti P. R3 nociceptive reflex in multiple sclerosis patients with paroxysmal symptoms treated with gabapentin. *Funct Neurol*. 2000;15:205-209.
38. Vu T-N. Current pharmacologic approaches to treating neuropathic pain. *Curr Pain Headache Rep*. 2004;8:15-18.
39. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): double blind crossover trial. *Diabetologia*. 1969;5:215-218.
40. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. *Arch Neurol*. 2004;61:914-918.
41. Gammaiton A, Gimbel JS, Hale M, Linn R, Galer BS. Lidocaine patch 5% effectively treats neuropathic pain qualities in low-back pain: results of a 6-week, prospective, open-label trial. *J Pain*. 2004;5(suppl 1):S2. Abstract 896.
42. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhofer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain*. 2003;105:71-78.
43. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. *Neurology*. 2003;60:927-934.
44. Reisner L. Antidepressants for chronic neuropathic pain. *Curr Pain Headache Rep*. 2003;7:24-33.
45. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. *Clin J Pain*. 2002;18(6 suppl):S155-S162.
46. Thant Z-S, Tan E-K. Emerging therapeutic applications of botulinum toxin. *Med Sci Monit*. 2003;9:RA40-RA48.
47. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. *Neurology*. 2001;56:1290-1293.
48. Ellis R, Hou J. New gains for pain. Available at: <http://www.pharmexec.com/pharmexec/content/printContentPopup.jsp?id=136704>. Accessed March 23, 2006.
49. Göbel H. Botulinum toxin in migraine prophylaxis. *J Neurol*. 2004;251(suppl 1):1/8-1/11.
50. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. *J Clin Pharmacol*. 2003;43:624-636.
51. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. *J Alzheimers Dis*. 2004;6(6 suppl):S61-S74.

Cancer Pain

References

1. Portenoy RK, Lesage P. Management of cancer pain. *Lancet*. 1999;353:1695-1700.
2. Katz N. Neuropathic pain in cancer and AIDS. *Clin J Pain*. 2000;16:S41-S48.
3. Siddall PJ, Cousins MJ. Introduction to pain mechanisms: implications for neural blockade. In: Cousins MJ, Bridenbaugh PO, eds. *Neural Blockade in Clinical Anesthesia and Management of Pain*. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1998:675-699.
4. Gamsa A. The role of psychological factors in chronic pain. I. A half century of study. *Pain*. 1994;57:5-15.
5. Gamsa A. The role of psychological factors in chronic pain. II. A critical appraisal. *Pain*. 1994;57:17-29.
6. American Pain Society. *Guideline for the Management of Cancer Pain in Adults and Children. APS Clinical Practice Guideline Series, No. 3*. Glenview, Ill: American Pain Society; 2005.
7. Cherny NI. The management of cancer pain. *CA—Cancer J Clin*. 2000;50:70-116.
8. American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. Available at: <http://www.asam.org/pain/definitions2.pdf>. Accessed March 23, 2006.
9. National Pharmaceutical Council, Inc, Joint Commission on Accreditation of Healthcare Organizations. *Pain: Current Understanding of Assessment, Management, and Treatments*. December 2001.
10. Fine PG, Portenoy RK. *A Clinical Guide to Opioid Analgesia*. Minneapolis, Minn: McGraw-Hill; 2004.
11. American Geriatrics Society Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons. *J Am Geriatr Soc*. 1998;46:635-651.
12. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. *Am J Ther*. 2001;8:181-186.
13. Fine PG. Opioid insights: opioid-induced hyperalgesia and opioid rotation. *J Pain Palliat Care Pharmacother*. 2004;18:75-79.
14. Bruera E, Kim HN. Cancer pain. *JAMA*. 2003;290:2476-2479.
15. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. *Am J Surg*. 2001;182(5A suppl):11S-18S.
16. Rajagopal A, Bruera ED. Improvement in sexual function after reduction of chronic high-dose opioid medication in a cancer survivor. *Pain Med*. 2003;4:379-383.
17. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. *J Clin Endocrinol Metab*. 2000;85:2215-2222.
18. Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex hormone suppression by intrathecal opioids: a prospective study. *Clin J Pain*. 2002;18:144-148.
19. American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and American Pain Society. Available at: <http://www.ampainsoc.org/advocacy/opioids.htm>. Accessed April 4, 2006.
20. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. *Clin J Pain*. 2000;16:251-254.
21. Savage SR, Covington E, Heit H, Hunt J, Joranson DE, Schnoll S, eds. *Definitions Related to the Use of Opioids for the Treatment of Pain: A Consensus Document From the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine*. Glenview, Ill: American Pain Society; 2001.
22. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. *Clin J Pain*. 1992;8:77-85.
23. Weissman DE, Haddox JD. Opioid pseudoaddiction—an iatrogenic syndrome. *Pain*. 1989;36:363-366.

Low Back Pain

References

1. Kent PM, Keating JL. The epidemiology of low back pain in primary care. *Chiropr Osteopat*. 2005;13:13.
2. Guo H-R, Tanaka S, Halperin WE, Cameron LL. Back pain prevalence in US industry and estimates of lost workdays. *Am J Public Health*. 1999;89:1029-1035.
3. Zagari MJ, Mazonson PD, Longton WC. Pharmacoeconomics of chronic nonmalignant pain. *Pharmacoeconomics*. 1996;10: 356-377.
4. Natvig B, Eriksen W, Bruusgaard D. Low back pain as a predictor of long-term work disability. *Scand J Public Health*. 2002;30: 288-292.
5. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. *J Occup Environ Med*. 2003;45:5-14.
6. Cohen RI, Chopra P, Upshur C. Low back pain, part 2: guide to conservative, medical, and procedural therapies. *Geriatrics*. 2001;56:38-47.
7. Deyo RA, Weinstein JN. Low back pain. *N Engl J Med*. 2001;344:363-370.
8. Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. *Ann Intern Med*. 2002;137:586-597.
9. Andersson GB. Epidemiological features of chronic low-back pain. *Lancet*. 1999;354:581-585.
10. Atkinson JH, Slater MA, Patterson TL, Grant I, Garfin SR. Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain: a controlled study. *Pain*. 1991;45:111-121.
11. Leino P, Magni G. Depressive and distress symptoms as predictors of low back pain, neck-shoulder pain, and other musculoskeletal morbidity: a 10-year follow-up of metal industry employees. *Pain*. 1993;53:89-94.
12. Polatin PB, Kinney RK, Gatchel RJ, Lillo E, Mayer TG. Psychiatric illness and chronic low-back pain: the mind and the spine—which goes first? *Spine*. 1993;18:66-71.
13. National Guideline Clearinghouse. Available at: <http://www.guideline.gov/>. Accessed February 9, 2005.
14. Bogduk N. Management of chronic low back pain. *Med J Aust*. 2004;180:79-83.
15. Cherkin DC, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain. *Ann Intern Med*. 2003;138:898-906.
16. Deyo RA, Phillips WR. Low back pain: a primary care challenge. *Spine*. 1996;21:2826-2832.
17. Nadler SF. Nonpharmacologic management of pain. *J Am Osteopath Assoc*. 2004;104(suppl 8):S6-S12.
18. Nielson WR, Weir R. Biopsychosocial approaches to the treatment of chronic pain. *Clin J Pain*. 2001;17:S114-S127.
19. Manheimer E, White A, Berman B, Forys K, Ernst E. Meta-analysis: acupuncture for low back pain. *Ann Intern Med*. 2005;142: 651-663.
20. Astin JA. Mind-body therapies for the management of pain. *Clin J Pain*. 2004;20:27-32.
21. Food and Drug Administration public health advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available at: <http://www.fda.gov/cder/drug/advisory/COX2.htm>. Accessed April 4, 2006.
22. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain: a randomized prospective study. *Spine*. 1998;23:2591-2600.
23. Kalso E, Allan L, Dobrogowski J, et al. Do strong opioids have a role in the early management of back pain? Recommendations from a European expert panel. *Curr Med Res Opin*. 2005;21:1819-1828.
24. Argoff CE. Topical treatments for pain. *Curr Pain Headache Rep*. 2004;8:261-267.
25. Thant Z-S, Tan E-K. Emerging therapeutic applications of botulinum toxin. *Med Sci Monit*. 2003;9:RA40-RA48.
26. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. *Neurology*. 2001;56:1290-1293.
27. National Library of Medicine/National Institutes of Health. Drug information: tramadol and acetaminophen (systemic). Available at: <http://www.nlm.nih.gov/medlineplus/print/druginfo/uspdi/500321.html>. Accessed May 2, 2006.
28. Peloso P, Rosenthal N, Jordan D, Karim R. Tramadol/acetaminophen combination tablets (Ultracet™) for chronic low back pain: pooled analysis. *J Pain*. 2004;4(suppl 1):26. Abstract 699.
29. Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal NR. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet®) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. *J Rheumatol*. 2004;31:2454-2463.
30. Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. *Am J Ther*. 2005;12:311-319.
31. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. *Drugs*. 1997;53:109-138.

Low Back Pain

References (cont)

32. Brennan M, Schein J, Vorsanger G, et al. Improvements in disability with fentanyl transdermal system treatment for chronic low back pain: results from an observational trial. *J Pain*. 2004;5(suppl 1):74. Abstract 864.
33. Allan L, Kalso E. Response to transdermal fentanyl or sustained release oral morphine in chronic low back pain. *J Pain*. 2004;5(suppl 1):69. Abstract 844.
34. Edwards K, Dreyer M. Botulinum toxin type A for failed back syndrome. *J Pain*. 2004;5(suppl 1):63. Abstract 817.
35. Edwards K, Dreyer M. Botulinum toxin A (Botox) for refractory low back pain. *J Pain*. 2003;4(suppl 1):28. Abstract 710.
36. Delamarter RB, Fribourg DM, Kanim LE, Bae H. ProDisc artificial total lumbar disc replacement: introduction and early results from the United States clinical trial. *Spine*. 2003;28:S167-S175.
37. Artificial lumbar disc. Available at: http://www.spinalneurosurgery.com/artificial_lumbar_disc.htm. Accessed March 24, 2006.

Migraine Pain

References

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache*. 2001;41:646-657.
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. *Arch Intern Med*. 1999;159:813-818.
3. Tzourio C, Tehindrazanarivo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. *BMJ*. 1995;310:830-833.
4. World Health Organization. Fact sheet. Headache disorders. Available at: <http://www.who.int/mediacentre/factsheets/fs277/en/print.html>. Accessed March 27, 2006.
5. Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. *Curr Neurol Neurosci Rep*. 2004;4:98-104.
6. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. *Am J Manag Care*. 2004;10:313-320.
7. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. *N Engl J Med*. 2002;346:257-270.
8. Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors, and co-morbidities. *Neurology*. 2001;56(6 suppl 1):S4-S12.
9. Gallagher RM, Cutrer FM. Migraine: diagnosis, management, and new treatment options. *Am J Manag Care*. 2002;8(3 suppl):S58-S73.
10. Joutel A, Bousser MG, Bioussse V, et al. A gene for familial hemiplegic migraine maps to chromosome 19. *Nat Genet*. 1993;5:40-45.
11. The International Classification of Headache Disorders: 2nd edition. *Cephalgia*. 2004;24(suppl 1):9-160.
12. Sandor PS, Ambrosini A, Agosti RM, Schoenen J. Genetics of migraine: possible links to neurophysiological abnormalities. *Headache*. 2002;42:365-377.
13. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. *BMJ*. 2005;330:63.
14. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. *Headache*. 2001;41:638-645.
15. Mannix LK, Calhoun AH. Menstrual migraine. *Curr Treat Options Neurol*. 2004;6:489-498.
16. Allaïs G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. *Neurol Sci*. 2004;25(suppl 3):S229-S231.
17. Martin VT. Menstrual migraine: a review of prophylactic therapies. *Curr Pain Headache Rep*. 2004;8:229-237.
18. Landy SH, Lobo BL. Migraine treatment throughout the lifecycle. *Expert Rev Neurother*. 2005;5:343-353.
19. Lainez M. Clinical benefits of early triptan therapy for migraine. *Cephalgia*. 2004;24(suppl 2):24-30.
20. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. *Headache*. 1990;30:705-709.
21. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. *Neurology*. 1998;51:307-309.
22. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. *Headache*. 2001;41:248-256.
23. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. *Neurology*. 2004;63:261-269.
24. Tuchman M. Oral zolmitriptan 2.5 mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches. *Headache*. 2005;45:771-772. Abstract OR713.
25. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000;55:754-763.

Osteoarthritis Pain

References

1. Manek NJ, Lane NE. Osteoarthritis: current concepts in diagnosis and management. *Am Fam Physician*. 2000;61:1795-1804.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum*. 1998;41:778-799.
3. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a clinical role? *Curr Rheumatol Rep*. 2001;3:513-519.
4. Hootman JM, Helmick CG, Schappert SM. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997. *Arthritis Rheum*. 2002;47:571-581.
5. National Pharmaceutical Council, Inc, Joint Commission on Accreditation of Healthcare Organizations. *Pain: Current Understanding of Assessment, Management, and Treatments*. December 2001.
6. Hinton R, Moody RL, Davis AW, Thomas SF. Osteoarthritis: diagnosis and therapeutic considerations. *Am Fam Physician*. 2002; 65:841-848.
7. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum*. 1998;41:1343-1355.
8. Swagerty DL Jr, Hellinger D. Radiographic assessment of osteoarthritis. *Am Fam Physician*. 2001;64:279-286.
9. Kantz ME, Harris WJ, Levitsky K, Ware JE Jr, Davies AR. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. *Med Care*. 1992;30(suppl):MS240-MS252.
10. American Pain Society. *Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis*. 2nd ed. Glenview, IL: American Pain Society; 2002.
11. Cohen RI, Chopra P, Upshur C. Low back pain, part 2: guide to conservative, medical, and procedural therapies. *Geriatrics*. 2001;56:38-47.
12. Ettinger WH Jr, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis: the Fitness Arthritis and Seniors Trial (FAST). *JAMA*. 1997;277:25-31.
13. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women: the Framingham Study. *Ann Intern Med*. 1992;116:535-539.
14. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum*. 2000;43:1905-1915.
15. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med*. 2006;354:795-808.
16. Food and Drug Administration public health advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available at: <http://www.fda.gov/cder/drug/advisory/COX2.htm>. Accessed April 4, 2006.
17. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. *Curr Med Res Opin*. 2004; 20(suppl 2):S13-S19.
18. Kivitz A, Ma C, Ahdieh H. Oxymorphone extended release improves pain and quality of life in patients with osteoarthritis: results of a randomized, double-blind, placebo-controlled, dose-ranging study. Paper presented at: The European League Against Rheumatism 2003 Congress; June 18-21, 2003; Lisbon, Portugal.
19. Gammaitoni A, Galer BS, Burch F, et al. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee. *J Pain*. 2003;4(suppl 1):78. Abstract 906.
20. Galer BS, Sheldon E, Patel N, Codding C, Burch F, Gammaitoni AR. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. *Curr Med Res Opin*. 2004;20:1455-1458.
21. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients: a prospective, multicenter, open-label effectiveness trial. *Osteoarthritis Cartilage*. 2004;12:253-255.
22. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *JAMA*. 2000;283:1469-1475.
23. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. *Arthritis Res Ther*. 2003;5:54-67.
24. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. *Connect Tissue Res*. 1999;40:1-11.
25. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. *Rheum Dis Clin North Am*. 1993;19:545-568.
26. American College of Rheumatology. Cartilage growth factor (TGF-S) in osteoarthritis. Available at: <http://www.rheumatology.org/publications/hotline/archive/0394cartilagegf.asp>. Accessed May 23, 2006.
27. Buckwalter JA, Mankin HJ. Articular cartilage repair and transplantation. *Arthritis Rheum*. 1998;41:1331-1342.

Pain Management in Older Adults

References

1. Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. *J Pain Symptom Manage.* 1995;10:591-598.
2. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. *Drugs Aging.* 2003;20:23-57.
3. Reyes-Gibby CC, Aday L, Cleland C. Impact of pain on self-rated health in the community-dwelling older adults. *Pain.* 2002;95: 75-82.
4. Baer WM, Hanson LC. Families' perception of the added value of hospice in the nursing home. *J Am Geriatr Soc.* 2000;48: 879-882.
5. Teno JM, Weitzner S, Wetle T, Mor V. Persistent pain in nursing home residents. *JAMA.* 2001;285:2081.
6. Cleary JF, Carbone PP. Palliative medicine in the elderly. *Cancer.* 1997;80:1335-1347.
7. Foley KM. Controlling cancer pain. *Hosp Pract.* 2000;35:101-108, 111-112.
8. Bernabei R, Gambassi G, Lapane K, et al; SAGE Study Group. Management of pain in elderly patients with cancer. *JAMA.* 1998; 279:1877-1882.
9. Morrison RS, Siu AL. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. *J Pain Symptom Manage.* 2000;19:240-248.
10. Weiner DK. Improving pain management for older adults: an urgent agenda for the educator, investigator, and practitioner [editorial]. *Pain.* 2002;97:1-4.
11. Baier RR, Gifford DR, Patry G, et al. Ameliorating pain in nursing homes: a collaborative quality-improvement project. *J Am Geriatr Soc.* 2004;52:1988-1995.
12. American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. *J Am Geriatr Soc.* 2002;50:S205-S224.
13. American Medical Directors Association. *Pain Management in the Long-Term Care Setting: Clinical Practice Guidelines.* Columbia, Md: American Medical Directors Association; 2004.
14. Attal N. Chronic neuropathic pain: mechanisms and treatment. *Clin J Pain.* 2000;16:S118-S130.
15. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum.* 2000;43:1905-1915.
16. Argoff CE. New analgesics for neuropathic pain: the lidocaine patch. *Clin J Pain.* 2000;16:S62-S66.
17. Gammaitoni A, Galer BS, Burch F, et al. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee. *J Pain.* 2003;4(suppl 1):78. Abstract 896.
18. Galer BS, Sheldon E, Patel N, Codding C, Burch F, Gammaitoni AR. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. *Curr Med Res Opin.* 2004;20:1455-1458.
19. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients: a prospective, multicenter, open-label effectiveness trial. *Osteoarthritis Cartilage.* 2004;12:253-255.
20. Weiner DK, Hanlon JT. Pain in nursing home residents: management strategies. *Drugs Aging.* 2001;18:13-29.
21. Gloth FM III. Pain management in older adults: prevention and treatment. *J Am Geriatr Soc.* 2001;49:188-199.
22. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. *JAMA.* 1994;272:1845-1850.
23. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. *Ann Intern Med.* 1991;115:787-796.
24. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. *Arch Intern Med.* 1993;153:1665-1670.
25. Food and Drug Administration issues caution on the use of COX-2s, but leaves open possibility for first-line use. *The Pink Sheet.* 2005;67:17.
26. Fine PG, Herr KA. Management of chronic pain in older persons: focus on safety, efficacy, and tolerability of pharmacologic therapy. *Pain Med News.* 2005;3:21-27.
27. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol.* 2003;60:1524-1534.
28. Guay DR. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? *Am J Geriatr Pharmacother.* 2005;3: 274-287.
29. Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. *Arch Intern Med.* 1996;156:1047-1052.
30. Max MB. Thirteen consecutive well-designed randomized trials show that antidepressants reduce pain in diabetic neuropathy and postherpetic neuralgia. *Pain Forum.* 1995;4:248-253.
31. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. *Anesth Analg.* 2005;101:1738-1749.

Opioid Therapy for Chronic Pain

References

1. American Chronic Pain Association. *Medications & Chronic Pain*. Rocklin, Calif: American Chronic Pain Association; 2005.
2. Portenoy RK. Opioid analgesics. In: Portenoy RK, Kanner RM, eds. *Pain Management: Theory and Practice*. Philadelphia, Pa: FA Davis Co; 1996:248-276.
3. Wall PD, Melzack R, eds. *Textbook of Pain*. 4th ed. New York, NY: Churchill Livingstone; 1999.
4. Fine PG, Portenoy RK. *A Clinical Guide to Opioid Analgesia*. Minneapolis, Minn: McGraw-Hill; 2004.
5. Fine PG. Opioid insights: opioid-induced hyperalgesia and opioid rotation. *J Pain Palliat Care Pharmacother*. 2004;18:75-79.
6. Bruera E, Kim HN. Cancer pain. *JAMA*. 2003;290:2476-2479.
7. Lazarus H, Fitzmartin RD, Goldenheim PD. A multi-investigator clinical evaluation of oral controlled-release morphine (MS Contin tablets) administered to cancer patients. *Hosp J*. 1990;6:1-15.
8. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. *Arch Intern Med*. 2000;160:853-860.
9. Kosinski MR, Schein JR, Vallaco SM. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. *Curr Med Res Opin*. 2005;21:849-862.
10. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain*. 2003;4:231-256.
11. American Pain Society. *Guideline for the Management of Cancer Pain in Adults and Children*. APS Clinical Practice Guideline Series, No. 3. Glenview, Ill: American Pain Society; 2005.
12. Savage SR, Covington E, Heit H, Hunt J, Joranson DE, Schnoll S, eds. *Definitions Related to the Use of Opioids for the Treatment of Pain: A Consensus Document From the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine*. Glenview, Ill: American Pain Society; 2001.
13. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. *Clin J Pain*. 1992;8:77-85.
14. Perry S, Heidrich G. Management of pain during debridement: a survey of U.S. burn units. *Pain*. 1982;13:267-280.
15. Medina JL, Diamond S. Drug dependency in patients with chronic headaches. *Headache*. 1977;17:12-14.
16. Saper JR, Lake AE III, Hamel RL, et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. *Neurology*. 2004;62:1687-1694.
17. Nedeljkovic SS, Wasan A, Jamison RN. Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. *Clin J Pain*. 2002;18(4 suppl):S39-S51.
18. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. *Pain*. 2004;112:65-75.

Chronic Pain in Primary Care/Managed Care Settings

References

1. National Institutes of Health, US Department of Health and Human Services. An update on NIH pain research and related program initiatives, December 2005. Available at: http://www.theacpa.org/documents/2005_12_08%20An%20Update%20of%20NIH%20Pain%20Research%20and%20Related%20Program%20Initiatives.pdf. Accessed May 17, 2006.
2. National Pharmaceutical Council, Inc, Joint Commission on Accreditation of Healthcare Organizations. *Pain: Current Understanding of Assessment, Management, and Treatments*. December 2001.
3. American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Practice guidelines for chronic pain management. *Anesthesiology*. 1997;86:995-1004.
4. American Pain Society. Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society. © 2000 American Pain Society.
5. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO). US pain management standards. Available at: http://www.whocancerpain.wisc.edu/eng/14_2/requirements.html. Accessed May 17, 2006.
6. Marcus DA. Managing chronic pain in the primary care setting. Available at: <http://www.aafp.org/afp/20020701/editorials.html>. Accessed May 17, 2006.